Search Results

Acasti Pharma Inc. announced that the Company will be participating in the BIO International Convention taking place at the San Diego Convention Center from June 3-6, 2024.

Acasti Pharma Inc. today announced financial results and business highlights for the year ended March 31, 2024.

Acasti Pharma Inc. announced that the Company’s pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone.

Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”

Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST) today announced financial and operational results for the fiscal year ended March 31, 2023.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine that addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage (aSAH), today announced financial results and business highlights for the quarter ended December 31, 2023.

Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.

Acasti Pharma Inc. today announced that the Company will effect a 1-for-6 reverse split of its issued and outstanding common shares.

Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company) today announced that a poster outlining its pivotal Phase 3 STRIVE-ON safety trial (the STRIVE-ON trial–NCT05995405) has been accepted for presentation at the 2024 International Stroke Conference, to be held February 7-9, 2024 in Phoenix, AZ.